期刊文献+

HBsAg定量与抗病毒治疗关系的研究进展 被引量:1

Research progress of correlation between HBsAg quantification and antiviral treatment in patients with chronic hepatitis B
下载PDF
导出
摘要 慢性乙型肝炎(chronic hepatitis B,CHB)抗病毒治疗持续应答(sustained response,SR)的预测依然是有待深入探讨的重要临床问题。近年来认识到HBsAg定量是一种非常重要的SR预测因子,也是CHB抗病毒治疗终点最理想的判断指标。本文全面介绍了慢性HBV感染者血清HBsAg水平的自然变化趋势、影响因素及其与抗病毒治疗的关系。 Prediction of sustained response (SR) to antiviral treatment in patients with chronic hepatitis B (CHB) remains an important clinical problem to be' deeply investigated. In recent years, HBsAg quantification has been recognized as a potent predictor of SR and an ideal endpoint of antiviral treatment for CHB. This article focuses on the natural trend of serum HBsAg level during chronic HBV infection, influential factors of HBsAg level and the correlation hetween serum HBsAg level and antiviral therapy in CHB patients.
出处 《传染病信息》 2013年第4期253-258,共6页 Infectious Disease Information
基金 南京军区"十一五"医药科技项目(09Z011 06MA63)
关键词 乙型肝炎表面抗原 乙型肝炎 慢性 治疗学 hepatitis B surface antigens hepatitis B, chronic therapeutics
  • 引文网络
  • 相关文献

参考文献1

共引文献45

同被引文献19

  • 1苏华科,马英梅.胸腺五肽联合干扰素治疗慢性乙型肝炎临床分析[J].实用医技杂志,2005,12(11B):3253-3254. 被引量:4
  • 2周荣乐,孙鑫,李攀,何林,赵连三,李幼平,Phil Wiffen(审校).胸腺肽α_1治疗HBeAg阳性慢性乙型肝炎疗效与安全性的随机对照试验的Meta分析[J].中国循证医学杂志,2006,6(3):189-194. 被引量:6
  • 3Hileman M. Critical overview and outlook: Pathogenesis,Prevention and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus[J]. Vaccine, 2003, 21(32): 4626-4649.
  • 4Yu Chen, Xuefen Li, Bo Ye, et al. Effect oftelbivudine therapy on the cellular immune response in chronic hepatitis B [J]. Antiviral Researc, 201 l, 91(1): 23-31.
  • 5Penna A, Chisari FV, Bertoletti A, et al. Cytotoxic T lymphocytes rec- ognize an HLA-A2-restficted epitope within the hepatitis B virus nu- cleocapsid antigen[J]. J Exp Med, 1991, 174(6): 1565-1570.
  • 6陈瑜.乙肝病毒感染的特异性CTL应答机制研究[D].浙江:浙江大学医学院,2001:1-40.
  • 7Niederau C, Heintges T, Lange S, et al. Long-term followup of HBeAg-positive patients treated with interferon alfa for chronic hep- atitis B[J]. N Engl J Med, 1996, 334(22): 1422-1427.
  • 8Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease [J]. N Engl J Med, 2004, 351(15): 1521-1531.
  • 9Di MV, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological re- sponse to lamivudine[J]. Hepatology, 2004, 40(4): 883-891.
  • 10C Boni, A Bertoletti, A Penna, et al. Lamivudine Treatment Can Re- store T Cell Responsiveness in Chronic Hepatitis B [J]. J Clin Invest, 1998, 102(5): 968-975.

引证文献1

二级引证文献4

;
使用帮助 返回顶部